Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome
Authors' conclusion
In patients with PCOS and high metabolic risk, OCP use resulted in improved HDL-C function and a mixed effect on lipoproteins and apolipoproteins, with no clear benefit from metformin.
Study context
- Population
- Patients with hyperandrogenic PCOS and elevated BMI with paired serum samples; two tertiary care reproductive endocrinology clinicsCholesterol efflux capacity (CEC) n = 129
- Participants
- 180 patients
- Comparison
- Metformin vs OCP vs OCP + metformin
- Primary endpoint
- Change in HDL-P, LDL-P, triglyceride-rich lipoprotein particles (TRL-P); apolipoproteins A-I, B and C-III; and CEC
- Follow-up
- 24 weeks
Methodological detailstwo tertiary care centres
- Two tertiary care centres
Primary result
As reported in the abstract
Advanced lipid phenotyping
CEC increased in the OCP arm; attenuated when adjusted for change in ApoA-I
adjusted ratio of geometric means 1.08, 95% CI 0.99-1.17
Original publication
Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome. Eur J Endocrinol. Published 13 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →